Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate.
The effect of indomethacin on the response of the NC carcinoma to methotrexate has been examined in vivo and in vitro. Survival was prolonged in mice treated with indomethacin 1.25 mg kg-1 twice daily plus methotrexate 4 mg kg-1 daily, compared to mice given either drug alone or controls. Indomethacin 1 microgram ml-1 increased the killing of cultured NC cells by methotrexate. This was not due to displacement of methotrexate from binding sites on the serum proteins. Nor was it due (entirely) to inhibition of prostaglandin synthesis, since flurbiprofen did not mimic the effect. Inhibition of cyclic AMP phosphodiesterase seems unlikely to explain the effect of indomethacin since theophylline had little or no effect on NC cell killing by methotrexate. Indomethacin 1 microgram ml-1 increased the accumulation of tritium in NC cells incubated with [3H]-methotrexate. In contrast, with normal epithelial cells from human embryonic intestine, indomethacin 1 microgram ml-1 did not alter the cytotoxicity of methotrexate or the accumulation of tritium during incubation with [3H]-methotrexate. The beneficial interaction between indomethacin and methotrexate may have therapeutic potential in man.
D000818:Animals; D000970:Antineoplastic Agents; D001798:Blood Proteins / Q000378:metabolism; D002460:Cell Line; D004357:Drug Synergism; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D008727:Methotrexate / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D009391:Nephelometry and Turbidimetry; D011485:Protein Binding
D000970:Antineoplastic Agents; D001798:Blood Proteins; D007213:Indomethacin; D008727:Methotrexate